Zanamivir
CLINICAL USE
Treatment of influenza A and B within 48 hours after onset of symptoms Post exposure prophylaxis
DOSE IN NORMAL RENAL FUNCTION
Treatment: 10 mg twice daily for 5 days Prophylaxis: 10 mg once daily for 10 days
PHARMACOKINETICS
Molecular weight                           : 332.3 %Protein binding                           : <10           : %Excreted unchanged in urine     : 100 Volume of distribution (L/kg)       : No data half-life – normal/ESRD (hrs)      : 2.6–5/Increased DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                : Unknown dialysability. Dose as in normal renal function HD                     : Unknown dialysability. Dose as in normal renal function HDF/high flux   : Unknown dialysability. Dose as in normal renal function CAV/VVHD      : Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs None known ADMINISTRATION
Reconstition
– Route
Inhalation Rate of Administration
– Comments
– OTHER INFORMATION
10 to 20 % of dose is systemically absorbed .
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home